risankizumab vs tildrakizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT02684370 · Phase 3 · completed
This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16.
Next expected readout: April 2028 · NCT04862286 (registry estimate)
Reported efficacy
Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 (Baseline, Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16; Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001 (met)
Result source: NCT02672852
tildrakizumab · Ilumya
Marketed by Sun Pharmaceutical Industries and partners
NCT01729754 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.
Next expected readout: September 2028 · NCT05390515 (registry estimate)
Reported efficacy
Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)); Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study) (Baseline and Week 12 (or end of trial if prior to Week 12)); Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study) (Up to 12 weeks): Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8% (met)
Result source: NCT01722331
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | risankizumab | tildrakizumab |
|---|---|---|
| PASI 75 | 85.2% vs 85.7%vs UstekinumabNCT0443560019 other results
| 66.3% vs 4.4%+61.9 vs placeboNCT0122573131 other results
|
| PASI 90 | 75.3% vs 4.9%+70.4 vs placeboNCT0268437022 other results
| 38.6% vs 2.4%+36.2 vs placeboNCT012257313 other results
|
| PASI 100 | 35.9% vs 0%+35.9 vs placeboNCT0268437020 other results
| 14.8% vs 0%+14.8 vs placeboNCT012257313 other results
|
| sPGA 0/1 | 87.8% vs 7.8%+80 vs placeboNCT0268437028 other results
| 61.8% vs 2.2%+59.6 vs placeboNCT012257313 other results
|
| DLQI, change | -17 vs -9.7vs FumadermNCT03255382 | -8.5 vs 1−9.5 vs placeboNCT012257313 other results
|
PASI 75
- risankizumab
- 85.2% vs 85.7%vs UstekinumabNCT04435600
19 other results
- 83.3% vs 85.7% NCT04435600
- 92.3% vs 85.7% NCT04435600
- 86.7% vs 85.7% NCT04435600
- 88.7% vs 8% NCT02672852
- 90.8% vs 6.1% NCT02684357
- 90.7% vs 71.7% NCT02694523
- 86.8% vs 70% NCT02684370
- 88.8% vs 69.7% NCT02684357
- 93.3% vs 26.7% NCT03255382
- 86.7% vs 20% NCT03255382
- 75% vs 8.3% NCT03255382
- 13.3% vs 3.3% NCT03255382
- 94.5% vs 8.6% NCT03000075
- 89.7% vs 8.6% NCT03000075
- 90.5% vs 77.5% NCT02054481
- 97.6% vs 77.5% NCT02054481
- 67.4% vs 77.5% NCT02054481
- 84.7% vs 18.8% NCT04908475
- 94% vs 77.5% NCT02054481
- tildrakizumab
- 66.3% vs 4.4%+61.9 vs placeboNCT01225731
31 other results
- 74.4% vs 4.4% NCT01225731
- 64.4% vs 4.4% NCT01225731
- 33.3% vs 4.4% NCT01225731
- 67.0% vs 4.9% NCT01225731
- 60.7% vs 4.4% NCT01225731
- 61.4% vs 4.8% NCT01225731
- 47.1% vs 4.7% NCT01225731
- 25% vs 2.3% NCT01225731
- 11.2% vs 0% NCT01225731
- 1.1% vs 0% NCT01225731
- 76.2% vs 4.9% NCT01225731
- 72.1% vs 4.4% NCT01225731
- 73.5% vs 4.8% NCT01225731
- 61.5% vs 4.7% NCT01225731
- 30.9% vs 2.3% NCT01225731
- 3.5% vs 0% NCT01225731
- 0% vs 0% NCT01225731
- 65.5% vs 4.9% NCT01225731
- 58.9% vs 4.4% NCT01225731
- 59.8% vs 4.8% NCT01225731
- 35.2% vs 4.7% NCT01225731
- 20.9% vs 2.3% NCT01225731
- 11.2% vs 0% NCT01225731
- 1.1% vs 0% NCT01225731
- 35% vs 4.9% NCT01225731
- 23.8% vs 4.4% NCT01225731
- 25% vs 4.8% NCT01225731
- 12.5% vs 4.7% NCT01225731
- 12.5% vs 2.3% NCT01225731
- 0% vs 0% NCT01225731
- 0% vs 0% NCT01225731
PASI 90
- risankizumab
- 75.3% vs 4.9%+70.4 vs placeboNCT02684370
22 other results
- 73.2% vs 2% NCT02672852
- 74.8% vs 2% NCT02684357
- 62.9% vs 3.8% NCT03875482
- 72.4% vs 47.4% NCT02694523
- 73.8% vs 65.6% NCT03478787
- 75.3% vs 42% NCT02684370
- 74.8% vs 47.5% NCT02684357
- 64.8% vs 60.7% NCT04435600
- 76.7% vs 11.7% NCT03255382
- 61.7% vs 5% NCT03255382
- 38.3% vs 1.7% NCT03255382
- 1.7% vs 0% NCT03255382
- 83.3% vs 60.7% NCT04435600
- 84.6% vs 60.7% NCT04435600
- 76.7% vs 60.7% NCT04435600
- 74.5% vs 1.7% NCT03000075
- 75.9% vs 1.7% NCT03000075
- 81% vs 40% NCT02054481
- 73.2% vs 40% NCT02054481
- 32.6% vs 40% NCT02054481
- 55.9% vs 5.1% NCT04908475
- 77.1% vs 40% NCT02054481
- tildrakizumab
- 38.6% vs 2.4%+36.2 vs placeboNCT01225731
3 other results
- 52.4% vs 2.4% NCT01225731
- 25.3% vs 2.4% NCT01225731
- 12.5% vs 2.4% NCT01225731
PASI 100
- risankizumab
- 35.9% vs 0%+35.9 vs placeboNCT02684370
20 other results
- 47.2% vs 1% NCT02672852
- 50.7% vs 2% NCT02684357
- 38.1% vs 1.9% NCT03875482
- 35.9% vs 12% NCT02684370
- 50.7% vs 24.2% NCT02684357
- 39.9% vs 23% NCT02694523
- 40.7% vs 17.9% NCT04435600
- 35% vs 1.7% NCT03255382
- 23.3% vs 1.7% NCT03255382
- 5% vs 1.7% NCT03255382
- 0% vs 0% NCT03255382
- 41.7% vs 17.9% NCT04435600
- 53.8% vs 17.9% NCT04435600
- 43.3% vs 17.9% NCT04435600
- 32.7% vs 0% NCT03000075
- 22.4% vs 0% NCT03000075
- 50% vs 17.5% NCT02054481
- 41.5% vs 17.5% NCT02054481
- 14% vs 17.5% NCT02054481
- 45.8% vs 17.5% NCT02054481
- tildrakizumab
- 14.8% vs 0%+14.8 vs placeboNCT01225731
3 other results
- 16.7% vs 0% NCT01225731
- 9.2% vs 0% NCT01225731
- 5% vs 0% NCT01225731
sPGA 0/1
- risankizumab
- 87.8% vs 7.8%+80 vs placeboNCT02684370
28 other results
- 83.5% vs 7% NCT02672852
- 83.7% vs 5.1% NCT02684357
- 78.1% vs 9.6% NCT03875482
- 83.7% vs 60.2% NCT02694523
- 79.6% vs 75% NCT04435600
- 68.5% vs 67.9% NCT04435600
- 83.3% vs 75% NCT04435600
- 84.6% vs 75% NCT04435600
- 90% vs 75% NCT04435600
- 83.3% vs 67.9% NCT04435600
- 84.6% vs 67.9% NCT04435600
- 83.3% vs 67.9% NCT04435600
- 32.2% vs 11.5% NCT04713592
- 87.8% vs 63% NCT02684370
- 83.7% vs 61.6% NCT02684357
- 82.2% vs 65% NCT02684370
- 82.3% vs 64.6% NCT02684357
- 91.7% vs 31.7% NCT03255382
- 90% vs 33.3% NCT03255382
- 81.7% vs 15% NCT03255382
- 33.3% vs 3.3% NCT03255382
- 75.4% vs 18.4% NCT04908475
- 92.7% vs 10.3% NCT03000075
- 86.2% vs 10.3% NCT03000075
- 90.5% vs 67.5% NCT02054481
- 90.2% vs 67.5% NCT02054481
- 62.8% vs 67.5% NCT02054481
- 90.4% vs 67.5% NCT02054481
- tildrakizumab
- 61.8% vs 2.2%+59.6 vs placeboNCT01225731
3 other results
- 74.4% vs 2.2% NCT01225731
- 57.8% vs 2.2% NCT01225731
- 33.3% vs 2.2% NCT01225731
DLQI, change
- risankizumab
- -17 vs -9.7vs FumadermNCT03255382
- tildrakizumab
- -8.5 vs 1−9.5 vs placeboNCT01225731
3 other results
- -8.8 vs 1 NCT01225731
- -9.2 vs 1 NCT01225731
- -4.9 vs 1 NCT01225731
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. risankizumab: 8 of 8 rows · tildrakizumab: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | risankizumab Rows use multiple source trials | tildrakizumab Rows use multiple source trials |
|---|---|---|
| DLQI 0/1 responder rate · % of participants No placebo or comparator arm | 47.1% (n=244) @ 52wk*a,b,c NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 115 Participants as posted | 56.3% (n=55) @ 52wk100 mga,b,c NCT03718299 · Phase 4 · registry result, not featured evidence |
| Itch NRS absolute change · score No placebo or comparator arm | -2.8 score @ 16wka,b,c NCT04435600 · Phase 3 | -3.8 score @ 16wk100 mga,b,c NCT03718299 · Phase 4 · registry result, not featured evidence |
| PASI absolute change · score Induction | -16.89 vs -9.11 Fumaderm score @ 16wkd,b,c NCT03255382 · Phase 3 · registry result, not featured evidence | -14.9 vs -2.4 placebo score @ 16wk100 mge,d,b,c NCT01225731 · Phase 2 · registry result, not featured evidence show 3 more doses-15.6 vs -2.4 placebo score @ 16wk200 mg NCT01225731 · Phase 2 · registry result, not featured evidence -14.6 vs -2.4 placebo score @ 16wk25 mg NCT01225731 · Phase 2 · registry result, not featured evidence -10 vs -2.4 placebo score @ 16wk5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| PASI 50 responder rate · % of participants Induction | 91.7% (n=12) vs 92.9% (n=28) Ustekinumab @ 16wke,d,b,c NCT04435600 · Phase 3 show 3 more doses90.7% (n=54) vs 92.9% (n=28) Ustekinumab @ 16wk NCT04435600 · Phase 3 100% (n=13) vs 92.9% (n=28) Ustekinumab @ 16wk NCT04435600 · Phase 3 96.7% (n=30) vs 92.9% (n=28) Ustekinumab @ 16wk NCT04435600 · Phase 3 | 82.02% (n=89) vs 8.89% (n=45) placebo @ 16wk100 mge,d,b,c NCT01225731 · Phase 2 · registry result, not featured evidence show 3 more doses91.86% (n=86) vs 8.89% (n=45) placebo @ 16wk200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 82.22% (n=90) vs 8.89% (n=45) placebo @ 16wk25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 57.14% (n=42) vs 8.89% (n=45) placebo @ 16wk5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 1.6%Risankizumab (Part A)f NCT02684370 · Phase 3 show 53 more results—Risankizumab/Risankizumab (Part B) NCT02684370 · Phase 3 1%Risankizumab (Part A1) NCT02672852 · Phase 3 —Risankizumab/Risankizumab (Part B; NCT02672852 · Phase 3 0%Part 1: Risankizumab NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Non-r NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Respo NCT04435600 · Phase 3 —Part 2 Period A: Risankizumab NCT04435600 · Phase 3 —Part 2 Period C: Risankizumab NCT04435600 · Phase 3 —Part 3: Risankizumab NCT04435600 · Phase 3 —Part 4: Risankizumab NCT04435600 · Phase 3 0.7%Risankizumab (Part A) NCT02684357 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02684357 · Phase 3 —Adalimumab/Rerandomized to Risanki NCT02694523 · Phase 3 —Adalimumab/Risankizumab (Part B) NCT02694523 · Phase 3 2.3%Risankizumab (Part A) NCT02694523 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02694523 · Phase 3 1.8%Study-G Risankizumab (Period A) NCT05969223 · Phase 4 —Study-G Risankizumab/Risankizumab NCT05969223 · Phase 4 0%Study-S Risankizumab (Period A) NCT05969223 · Phase 4 —Study-S Risankizumab/Risankizumab NCT05969223 · Phase 4 —Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 26.2%150 mg NCT03047395 · Phase 3 · registry result, not featured evidence 3.4%Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab (Double-blind Period) NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab (Open-la NCT04713592 · Phase 3 · registry result, not featured evidence 16% NCT04102007 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 11.1% NCT03875508 · Phase 3 · registry result, not featured evidence 12.4% NCT03875482 · Phase 3 · registry result, not featured evidence 7.9% NCT03478787 · Phase 3 · registry result, not featured evidence 0% NCT03255382 · Phase 3 · registry result, not featured evidence 70%600 mg NCT05283135 · Phase 2 · registry result, not featured evidence 70%300 mg NCT05283135 · Phase 2 · registry result, not featured evidence —180 mg NCT02203851 · Phase 2 · registry result, not featured evidence —90 mg NCT02203851 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 4.8%180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 4.9%90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 9.3%18 mg NCT02054481 · Phase 2 · registry result, not featured evidence | —100 mgf NCT01729754 · Phase 3 · monotherapy show 24 more results—200 mg NCT01729754 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy 15.7%100 mg NCT03897075 · Phase 3 —100 mg NCT03897075 · Phase 3 16.7% NCT04271540 · Phase 4 · registry result, not featured evidence 0% NCT04541329 · Phase 4 · registry result, not featured evidence 18.2%100 mg NCT03718299 · Phase 4 · registry result, not featured evidence 1.1%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.3%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 5.4%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 4.8%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.3%Risankizumab (Part A)f NCT02684370 · Phase 3 show 53 more results—Risankizumab/Risankizumab (Part B) NCT02684370 · Phase 3 0.2%Risankizumab (Part A1) NCT02672852 · Phase 3 —Risankizumab/Risankizumab (Part B; NCT02672852 · Phase 3 —Part 1: Risankizumab NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Non-r NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Respo NCT04435600 · Phase 3 —Part 2 Period A: Risankizumab NCT04435600 · Phase 3 —Part 2 Period C: Risankizumab NCT04435600 · Phase 3 —Part 3: Risankizumab NCT04435600 · Phase 3 —Part 4: Risankizumab NCT04435600 · Phase 3 0%Risankizumab (Part A) NCT02684357 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02684357 · Phase 3 —Adalimumab/Rerandomized to Risanki NCT02694523 · Phase 3 —Adalimumab/Risankizumab (Part B) NCT02694523 · Phase 3 1%Risankizumab (Part A) NCT02694523 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02694523 · Phase 3 —Study-G Risankizumab (Period A) NCT05969223 · Phase 4 —Study-G Risankizumab/Risankizumab NCT05969223 · Phase 4 —Study-S Risankizumab (Period A) NCT05969223 · Phase 4 —Study-S Risankizumab/Risankizumab NCT05969223 · Phase 4 —Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 6.5%150 mg NCT03047395 · Phase 3 · registry result, not featured evidence 1.1%Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab (Double-blind Period) NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab (Open-la NCT04713592 · Phase 3 · registry result, not featured evidence 1.6% NCT04102007 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 0.9% NCT03875508 · Phase 3 · registry result, not featured evidence 0% NCT03875482 · Phase 3 · registry result, not featured evidence 0.6% NCT03478787 · Phase 3 · registry result, not featured evidence 0% NCT03255382 · Phase 3 · registry result, not featured evidence —600 mg NCT05283135 · Phase 2 · registry result, not featured evidence —300 mg NCT05283135 · Phase 2 · registry result, not featured evidence —180 mg NCT02203851 · Phase 2 · registry result, not featured evidence —90 mg NCT02203851 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 2.4%90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 2.3%18 mg NCT02054481 · Phase 2 · registry result, not featured evidence | —100 mgf NCT01729754 · Phase 3 · monotherapy show 24 more results—200 mg NCT01729754 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT03897075 · Phase 3 —100 mg NCT03897075 · Phase 3 — NCT04271540 · Phase 4 · registry result, not featured evidence — NCT04541329 · Phase 4 · registry result, not featured evidence 1.8%100 mg NCT03718299 · Phase 4 · registry result, not featured evidence 1.1%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.2%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.2%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.4%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 2.3%Risankizumab (Part A)f NCT02684370 · Phase 3 show 53 more results5.4%Risankizumab/Risankizumab (Part B) NCT02684370 · Phase 3 2%Risankizumab (Part A1) NCT02672852 · Phase 3 11.7%Risankizumab/Risankizumab (Part B; NCT02672852 · Phase 3 0%Part 1: Risankizumab NCT04435600 · Phase 3 10%Part 2 Period A Risankizumab Non-r NCT04435600 · Phase 3 0%Part 2 Period A Risankizumab Respo NCT04435600 · Phase 3 0%Part 2 Period A: Risankizumab NCT04435600 · Phase 3 0%Part 2 Period C: Risankizumab NCT04435600 · Phase 3 0%Part 3: Risankizumab NCT04435600 · Phase 3 0%Part 4: Risankizumab NCT04435600 · Phase 3 2%Risankizumab (Part A) NCT02684357 · Phase 3 4.5%Risankizumab/Risankizumab (Part B) NCT02684357 · Phase 3 5.7%Adalimumab/Rerandomized to Risanki NCT02694523 · Phase 3 10.5%Adalimumab/Risankizumab (Part B) NCT02694523 · Phase 3 3.3%Risankizumab (Part A) NCT02694523 · Phase 3 4.1%Risankizumab/Risankizumab (Part B) NCT02694523 · Phase 3 1.8%Study-G Risankizumab (Period A) NCT05969223 · Phase 4 1.9%Study-G Risankizumab/Risankizumab NCT05969223 · Phase 4 5.9%Study-S Risankizumab (Period A) NCT05969223 · Phase 4 5.9%Study-S Risankizumab/Risankizumab NCT05969223 · Phase 4 0.8%Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence 0%Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 2.9%Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence 6.9%Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 20%150 mg NCT03047395 · Phase 3 · registry result, not featured evidence —Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence 5.7%Risankizumab (Double-blind Period) NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence 6%Risankizumab/Risankizumab (Open-la NCT04713592 · Phase 3 · registry result, not featured evidence 7% NCT04102007 · Phase 3 · registry result, not featured evidence 25%150 mg NCT03022045 · Phase 3 · registry result, not featured evidence 50%150 mg NCT03022045 · Phase 3 · registry result, not featured evidence 20%75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 0%75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 5.6% NCT03875508 · Phase 3 · registry result, not featured evidence 1% NCT03875482 · Phase 3 · registry result, not featured evidence 5.5% NCT03478787 · Phase 3 · registry result, not featured evidence 1.7% NCT03255382 · Phase 3 · registry result, not featured evidence 0%600 mg NCT05283135 · Phase 2 · registry result, not featured evidence 10%300 mg NCT05283135 · Phase 2 · registry result, not featured evidence 8.7%180 mg NCT02203851 · Phase 2 · registry result, not featured evidence 13.8%90 mg NCT02203851 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 3.6%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 1.9%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 7.4%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 3.4%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 1.8%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 14.6%90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 11.6%18 mg NCT02054481 · Phase 2 · registry result, not featured evidence | 6.2%100 mgf NCT01729754 · Phase 3 · monotherapy show 24 more results4.9%200 mg NCT01729754 · Phase 3 · monotherapy 1.6%100 mg NCT01722331 · Phase 3 · monotherapy 1.9%100 mg NCT01722331 · Phase 3 · monotherapy 4.4%100 mg NCT01722331 · Phase 3 · monotherapy 2.6%200 mg NCT01722331 · Phase 3 · monotherapy 2.2%200 mg NCT01722331 · Phase 3 · monotherapy 5.8%200 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT03897075 · Phase 3 5.9%100 mg NCT03897075 · Phase 3 0% NCT04271540 · Phase 4 · registry result, not featured evidence 0% NCT04541329 · Phase 4 · registry result, not featured evidence 7.3%100 mg NCT03718299 · Phase 4 · registry result, not featured evidence 1.1%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 3.9%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.5%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.3%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 3.8%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.7%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.1%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 5.3%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.1%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | f viral upper respiratory tract infection 6.6% (placebo 5.9%) upper respiratory tract infection 5.6% (placebo 2%) headache 3% (placebo 2%) NCT02684370 · Phase 3 show 48 more resultsviral upper respiratory tract infection 13.5% (placebo 5.9%) upper respiratory tract infection 10.1% (placebo 2%) headache 1.7% (placebo 2%) NCT02684370 · Phase 3 nasopharyngitis 5.2% (placebo 6%) headache 3.4% (placebo 0%) arthralgia 1.7% (placebo 2%) NCT02672852 · Phase 3 nasopharyngitis 20.7% (placebo 6%) upper respiratory tract infection 14.4% (placebo 5%) arthralgia 9% (placebo 2%) NCT02672852 · Phase 3 headache 16.7% (placebo 4.8%) pyrexia 16.7% (placebo 0%) abdominal pain 8.3% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 40% (placebo 9.5%) covid-19 20% (placebo 9.5%) conjunctivitis 10% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 22.7% (placebo 9.5%) headache 18.2% (placebo 4.8%) skin papilloma 13.6% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 18.5% (placebo 9.5%) covid-19 9.3% (placebo 9.5%) headache 5.6% (placebo 4.8%) NCT04435600 · Phase 3 pyrexia 25% (placebo 0%) bacterial vaginosis 12.5% (placebo 0%) chills 12.5% (placebo 0%) NCT04435600 · Phase 3 cough 15.4% (placebo 4.8%) upper respiratory tract infection 15.4% (placebo 4.8%) blood potassium increased 7.7% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 31.3% (placebo 9.5%) pyrexia 12.5% (placebo 0%) cough 9.4% (placebo 4.8%) NCT04435600 · Phase 3 upper respiratory tract infection 3.7% (placebo 2%) viral upper respiratory tract infection 3.4% (placebo 2%) influenza 2% (placebo 1%) NCT02684357 · Phase 3 viral upper respiratory tract infection 11.7% (placebo 2%) upper respiratory tract infection 8.2% (placebo 2%) diarrhoea 2.1% (placebo 3.1%) NCT02684357 · Phase 3 viral upper respiratory tract infection 26.4% upper respiratory tract infection 7.5% headache 5.7% NCT02694523 · Phase 3 viral upper respiratory tract infection 23.7% hypertension 7.9% upper respiratory tract infection 7.9% NCT02694523 · Phase 3 viral upper respiratory tract infection 8.6% upper respiratory tract infection 7% headache 4% NCT02694523 · Phase 3 viral upper respiratory tract infection 13.3% upper respiratory tract infection 11.6% hypertension 3.1% NCT02694523 · Phase 3 upper respiratory tract infection 7.3% (placebo 3.7%) covid-19 3.6% (placebo 3.7%) nasopharyngitis 3.6% (placebo 3.7%) NCT05969223 · Phase 4 upper respiratory tract infection 7.4% (placebo 3.7%) covid-19 3.7% (placebo 3.7%) nasopharyngitis 3.7% (placebo 3.7%) NCT05969223 · Phase 4 upper respiratory tract infection 11.8% (placebo 3.7%) covid-19 7.8% (placebo 3.7%) nasopharyngitis 2% (placebo 3.7%) NCT05969223 · Phase 4 upper respiratory tract infection 11.8% (placebo 3.7%) covid-19 7.8% (placebo 3.7%) nasopharyngitis 2% (placebo 3.7%) NCT05969223 · Phase 4 covid-19 11% nasopharyngitis 3.4% headache 2.5% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 12.5% nasopharyngitis 10.4% hypertension 6.3% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 11.8% nasopharyngitis 9.8% upper respiratory tract infection 5.9% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 16.4% nasopharyngitis 9.5% hypertension 5.2% NCT04908475 · Phase 4 · registry result, not featured evidence 150 mg nasopharyngitis 22.1% covid-19 16.6% upper respiratory tract infection 14.4% NCT03047395 · Phase 3 · registry result, not featured evidence covid-19 2.3% (placebo 2.3%) NCT04713592 · Phase 3 · registry result, not featured evidence covid-19 14.3% (placebo 2.3%) NCT04713592 · Phase 3 · registry result, not featured evidence 150 mg viral upper respiratory tract infection 75% otitis media 50% acne 25% NCT03022045 · Phase 3 · registry result, not featured evidence 150 mg dehydration 50% abdominal pain upper 25% acne 25% NCT03022045 · Phase 3 · registry result, not featured evidence 75 mg viral upper respiratory tract infection 60% constipation 20% diarrhoea 20% NCT03022045 · Phase 3 · registry result, not featured evidence 75 mg alanine aminotransferase increased 25% aspartate aminotransferase increased 25% erythema 25% NCT03022045 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.4% upper respiratory tract infection 5.6% NCT03875508 · Phase 3 · registry result, not featured evidence nasopharyngitis 21.3% upper respiratory tract infection 12.8% arthralgia 5.5% NCT03478787 · Phase 3 · registry result, not featured evidence nasopharyngitis 58.3% headache 8.3% oropharyngeal pain 8.3% NCT03255382 · Phase 3 · registry result, not featured evidence 600 mg upper respiratory infection 50% common cold 30% covid-19 infection 30% NCT05283135 · Phase 2 · registry result, not featured evidence 300 mg upper respiratory infection 20% bleeding internal hemorrhoids 10% bursitis, left elbow 10% NCT05283135 · Phase 2 · registry result, not featured evidence 180 mg upper respiratory tract infection 17.4% dermatitis contact 13% nasopharyngitis 13% NCT02203851 · Phase 2 · registry result, not featured evidence 90 mg nasopharyngitis 18.4% upper respiratory tract infection 12.6% arthralgia 10.3% NCT02203851 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 29.6% (placebo 13.8%) arthralgia 11.1% (placebo 1.7%) oral herpes 7.4% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 18.2% (placebo 13.8%) arthralgia 3.6% (placebo 1.7%) back pain 1.8% (placebo 1.7%) NCT03000075 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 20.4% (placebo 13.8%) dental caries 7.4% (placebo 1.7%) blood triglycerides increased 5.6% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 75 mg nasopharyngitis 29.6% (placebo 13.8%) arthralgia 11.1% (placebo 1.7%) asteatosis 7.4% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 75 mg diabetes mellitus 5.2% (placebo 1.7%) nasopharyngitis 5.2% (placebo 13.8%) back pain 3.4% (placebo 1.7%) NCT03000075 · Phase 2 · registry result, not featured evidence 75 mg nasopharyngitis 21.4% (placebo 13.8%) hepatic function abnormal 5.4% (placebo 0%) influenza 5.4% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 180 mg nasopharyngitis 26.2% arthralgia 7.1% headache 7.1% NCT02054481 · Phase 2 · registry result, not featured evidence 90 mg nasopharyngitis 34.1% back pain 9.8% gastroenteritis 9.8% NCT02054481 · Phase 2 · registry result, not featured evidence 18 mg nasopharyngitis 34.9% headache 11.6% folliculitis 7% NCT02054481 · Phase 2 · registry result, not featured evidence | 100 mgf nasopharyngitis 23% (placebo 7.7%) headache 6% (placebo 3.8%) arthralgia 5.3% (placebo 1.9%) NCT01729754 · Phase 3 · monotherapy show 22 more results200 mg nasopharyngitis 22.6% (placebo 7.7%) headache 5.7% (placebo 3.8%) upper respiratory tract infection 5.1% (placebo 0.6%) NCT01729754 · Phase 3 · monotherapy 100 mg nasopharyngitis 7.8% (placebo 5.2%) upper respiratory tract infection 3.2% (placebo 5.8%) psoriasis 0.6% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 100 mg nasopharyngitis 6.4% (placebo 5.2%) upper respiratory tract infection 4.3% (placebo 5.8%) psoriasis 0.5% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 100 mg nasopharyngitis 15.2% (placebo 5.2%) upper respiratory tract infection 8.2% (placebo 5.8%) psoriasis 2.8% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 200 mg nasopharyngitis 6.5% (placebo 5.2%) upper respiratory tract infection 4.9% (placebo 5.8%) psoriasis 0% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 200 mg upper respiratory tract infection 5.4% (placebo 5.8%) nasopharyngitis 4.6% (placebo 5.2%) psoriasis 0.8% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 200 mg nasopharyngitis 12.2% (placebo 5.2%) upper respiratory tract infection 10.3% (placebo 5.8%) psoriasis 2.5% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 100 mg covid-19 11.8% (placebo 10.4%) skin and subcutaneous tissue disorders 9.8% (placebo 4.2%) upper respiratory tract infection 9.8% (placebo 8.3%) NCT03897075 · Phase 3 covid infection 9.7% NCT04271540 · Phase 4 · registry result, not featured evidence 100 mg psoriasis 12.7% hypertension 9.1% dermatitis 5.5% NCT03718299 · Phase 4 · registry result, not featured evidence 100 mg nasopharyngitis 14.6% (placebo 20%) diarrhoea 6.7% (placebo 6.7%) headache 6.7% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 22.2% (placebo 20%) headache 8.5% (placebo 8.9%) back pain 5.2% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 8.8% (placebo 20%) back pain 3.6% (placebo 0%) headache 3.6% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 12.8% (placebo 20%) headache 8.1% (placebo 8.9%) pruritus 4.7% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 16.5% (placebo 20%) gastroenteritis 6.3% (placebo 2.2%) upper respiratory tract infection 5.1% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 6.7% (placebo 20%) upper respiratory tract infection 4% (placebo 0%) bronchiitis 2.7% (placebo 4.4%) NCT01225731 · Phase 2 · registry result, not featured evidence 25 mg nasopharyngitis 13.2% (placebo 20%) diarrhoea 5.5% (placebo 6.7%) headache 5.5% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 25 mg nasopharyngitis 25.5% (placebo 20%) gastroenteritis 5.3% (placebo 2.2%) back pain 4.3% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 25 mg nasopharyngitis 6.9% (placebo 20%) back pain 3.4% (placebo 0%) bronchiitis 2.3% (placebo 4.4%) NCT01225731 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 16.7% (placebo 20%) bronchiitis 7.1% (placebo 4.4%) cough 7.1% (placebo 4.4%) NCT01225731 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 23.1% (placebo 20%) acute tonsilitis 7.7% (placebo 0%) blood pressure systolic increased 7.7% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 5 mg abdominal pain upper 8.3% (placebo 0%) back pain 8.3% (placebo 0%) dyspnoea 8.3% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dTrial phases differ: Phase 3 versus Phase 2.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
risankizumab
show 15 more results
show 7 more results
show 3 more results
show 12 more results
show 4 more results
show 13 more results
show 15 more results
show 9 more results
+ 38 further endpoints in the CSV export.
tildrakizumab
show 5 more results
show 5 more results
show 11 more results
show 11 more results
show 5 more results
show 11 more results
show 5 more results
show 11 more results
show 5 more results
show 11 more results
show 5 more results
show 11 more results
+ 24 further endpoints in the CSV export.
Psoriatic Arthritis
Shared mechanism: IL-23 p19 · full Psoriatic Arthritis pipeline
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03675308 · Phase 3 · active, not recruiting
Randomized, double-blind, placebo-controlled trial in 964 patients with a validated clinical response measure (ACR20 at week 24) as the primary endpoint, which risankizumab met (57.3% vs 33.5%, p<0.001). The protocol and the published report state a power calculation for the ACR20 endpoint based on about 880 patients, and 964 were randomized.
Next expected readout: August 2029 · NCT06865105 (registry estimate)
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8) (met)
Result source: NCT03675308
tildrakizumab · Ilumya
Marketed by Sun Pharmaceutical Industries and partners
NCT04314544 · Phase 3 · completed
The study randomized 508 participants to tildrakizumab or placebo, with outcome assessors masked, and used the clinical ACR20 response as its primary endpoint. However, no results are posted, so whether the primary endpoint was met or missed is unknown.
Next expected readout: December 2028 · NCT04991116 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | risankizumab | tildrakizumab |
|---|---|---|
| ACR20 | 61.9% vs 35.7%+26.2 vs placeboNCT027191715 other results
| 0.8% vs 0.5%+0.3 vs placeboNCT029806923 other results
|
| ACR50 | 23.8% vs 11.9%+11.9 vs placeboNCT027191715 other results
| —Not posted · NCT04314544 |
| PASI 75 | —Not posted · NCT06624228 | —Not posted · NCT04314544 |
| Minimal disease activity | —Not posted · NCT06624228 | —Not posted · NCT04314544 |
| HAQ-DI, change | -0.2 vs -0.1−0.1 vs placeboNCT027191715 other results
| —Not posted · NCT04314544 |
ACR20
- risankizumab
- 61.9% vs 35.7%+26.2 vs placeboNCT02719171
5 other results
- 59% vs 35.7% NCT02719171
- 60.5% vs 35.7% NCT02719171
- 57.1% vs 35.7% NCT02719171
- 59.5% vs 35.7% NCT02719171
- 65% vs 35.7% NCT02719171
- tildrakizumab
- 0.8% vs 0.5%+0.3 vs placeboNCT02980692
3 other results
- 0.8% vs 0.5% NCT02980692
- 0.7% vs 0.5% NCT02980692
- 0.7% vs 0.5% NCT02980692
ACR50
- risankizumab
- 23.8% vs 11.9%+11.9 vs placeboNCT02719171
5 other results
- 38.5% vs 11.9% NCT02719171
- 30.9% vs 11.9% NCT02719171
- 23.8% vs 11.9% NCT02719171
- 23.8% vs 11.9% NCT02719171
- 25% vs 11.9% NCT02719171
- tildrakizumab
- —Not posted · NCT04314544
PASI 75
- risankizumab
- —Not posted · NCT06624228
- tildrakizumab
- —Not posted · NCT04314544
Minimal disease activity
- risankizumab
- —Not posted · NCT06624228
- tildrakizumab
- —Not posted · NCT04314544
HAQ-DI, change
- risankizumab
- -0.2 vs -0.1−0.1 vs placeboNCT02719171
5 other results
- -0.2 vs -0.1 NCT02719171
- -0.2 vs -0.1 NCT02719171
- -0.2 vs -0.1 NCT02719171
- -0.2 vs -0.1 NCT02719171
- -0.1 vs -0.1 NCT02719171
- tildrakizumab
- —Not posted · NCT04314544
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. risankizumab: 6 of 6 rows · tildrakizumab: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | risankizumab Rows use multiple source trials | tildrakizumab |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 75.2% (n=101) @ 52wka,b NCT02986373 · Phase 2 · registry result, not featured evidence | 0.8667% (n=60) @ 52wkDose IIIc,a,b NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses0.8133% (n=75) @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence 0.9254% (n=67) @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence 0.8906% (n=64) @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| HAQ-DI absolute change · score No placebo or comparator arm | -0.318 score @ 52wka,b NCT02986373 · Phase 2 · registry result, not featured evidence | -0.4857 score @ 52wkDose IIIc,a,b NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses-0.4583 score @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence -0.4869 score @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence -0.543 score @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| Dropout rate | —150 mgd NCT03671148 · Phase 3 show 5 more results26.9% NCT02986373 · Phase 2 · registry result, not featured evidence 5.1%150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence 7.1%150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 9.5%150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 10%75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence | 100%200 mg q12 Weeksd NCT03552276 · Phase 2/3 · registry result, not featured evidence show 23 more results16.6%200 mg q12 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q12 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 100%200 mg q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 14.8%200 mg q4 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg, q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg, q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 32.7%100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence 22.1%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 9%Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence 20.5%I NCT02980692 · Phase 2 · registry result, not featured evidence 19%II NCT02980692 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —150 mgd NCT03671148 · Phase 3 show 5 more results2.8% NCT02986373 · Phase 2 · registry result, not featured evidence 0%150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence 0%150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 4.8%150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 10%75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence | —200 mg q12 Weeksd NCT03552276 · Phase 2/3 · registry result, not featured evidence show 23 more results—200 mg q12 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q12 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg, q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg, q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 2.6%Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%I NCT02980692 · Phase 2 · registry result, not featured evidence 2.5%II NCT02980692 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4%150 mgd NCT03671148 · Phase 3 show 5 more results3.4% NCT02986373 · Phase 2 · registry result, not featured evidence 5.1%150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence 0%150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 7.1%150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 15%75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence | —200 mg q12 Weeksd NCT03552276 · Phase 2/3 · registry result, not featured evidence show 23 more results—200 mg q12 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 16.6%200 mg q12 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 5.6%200 mg q4 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 9.1%200 mg, q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 60%200 mg, q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 14.3%100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 2.6%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence 2.5%II NCT02980692 · Phase 2 · registry result, not featured evidence 2.6%I NCT02980692 · Phase 2 · registry result, not featured evidence 0%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 0%II NCT02980692 · Phase 2 · registry result, not featured evidence 0%I NCT02980692 · Phase 2 · registry result, not featured evidence 3.8%Dose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%II NCT02980692 · Phase 2 · registry result, not featured evidence 3.8%I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 5 more resultsviral upper respiratory tract infection 11% NCT02986373 · Phase 2 · registry result, not featured evidence 150 mg weeks 0 and 12 viral upper respiratory tract infection 23.1% (placebo 4.8%) headache 7.7% (placebo 7.1%) abdominal pain 5.1% (placebo 2.4%) NCT02719171 · Phase 2 · registry result, not featured evidence 150 mg weeks 0, 4, and 16 viral upper respiratory tract infection 11.9% (placebo 4.8%) upper respiratory tract infection 7.1% (placebo 11.9%) back pain 4.8% (placebo 2.4%) NCT02719171 · Phase 2 · registry result, not featured evidence 150 mg every 4 weeks viral upper respiratory tract infection 16.7% (placebo 4.8%) cough 7.1% (placebo 4.8%) fatigue 7.1% (placebo 0%) NCT02719171 · Phase 2 · registry result, not featured evidence 75 mg week 0 viral upper respiratory tract infection 20% (placebo 4.8%) abdominal discomfort 5% (placebo 0%) alanine aminotransferase increased 5% (placebo 2.4%) NCT02719171 · Phase 2 · registry result, not featured evidence | 200 mg q12 Weeks, to 100 mg q12 Weeksd covid-19 16.6% nasopharyngitis 13.9% urinary tract infection 11.9% NCT03552276 · Phase 2/3 · registry result, not featured evidence show 15 more results200 mg q4 Weeks, to 100 mg q12 Weeks covid-19 20.4% upper respiratory tract infection 16.7% nasopharyngitis 14.8% NCT03552276 · Phase 2/3 · registry result, not featured evidence 200 mg, q12 Weeks diarrhoea 18.2% arthralgia 13.6% arthritis 9.1% NCT03552276 · Phase 2/3 · registry result, not featured evidence 200 mg, q4 Weeks hypertension 40% abdominal abscess 20% alanine aminotransferase increased 20% NCT03552276 · Phase 2/3 · registry result, not featured evidence 100 mg q12 Weeks nasopharyngitis 14.3% upper respiratory tract infection 14.3% abdominal pain 8.2% NCT03552276 · Phase 2/3 · registry result, not featured evidence Dose III headache 6.5% (placebo 3.8%) nasopharyngitis 5.2% (placebo 6.3%) upper respiratory tract infection 3.9% (placebo 1.3%) NCT02980692 · Phase 2 · registry result, not featured evidence Dose IV diarrhoea 6.4% (placebo 0%) headache 6.4% (placebo 3.8%) nasopharyngitis 6.4% (placebo 6.3%) NCT02980692 · Phase 2 · registry result, not featured evidence II hypertension 7.6% (placebo 6.3%) sleep disorder 6.3% (placebo 1.3%) upper respiratory tract infection 5.1% (placebo 1.3%) NCT02980692 · Phase 2 · registry result, not featured evidence I nasopharyngitis 9% (placebo 6.3%) headache 5.1% (placebo 3.8%) hypertension 3.8% (placebo 6.3%) NCT02980692 · Phase 2 · registry result, not featured evidence Dose III headache 2.6% (placebo 3.8%) nasopharyngitis 2.6% (placebo 6.3%) upper respiratory tract infection 2.6% (placebo 1.3%) NCT02980692 · Phase 2 · registry result, not featured evidence II upper respiratory tract infection 5.1% (placebo 1.3%) headache 3.8% (placebo 3.8%) nasopharyngitis 2.5% (placebo 6.3%) NCT02980692 · Phase 2 · registry result, not featured evidence I hypertension 5.1% (placebo 6.3%) upper respiratory tract infection 3.8% (placebo 1.3%) aspartate aminotransferase increased 2.6% (placebo 0%) NCT02980692 · Phase 2 · registry result, not featured evidence Dose IV then SUNPG1623 II nasopharyngitis 9% (placebo 6.3%) upper respiratory tract infection 5.1% (placebo 1.3%) urinary tract infection 5.1% (placebo 3.8%) NCT02980692 · Phase 2 · registry result, not featured evidence Dose III headache 1.3% (placebo 3.8%) nasopharyngitis 1.3% (placebo 6.3%) upper respiratory tract infection 1.3% (placebo 1.3%) NCT02980692 · Phase 2 · registry result, not featured evidence II aspartate aminotransferase increased 1.3% (placebo 0%) diarrhoea 0% (placebo 0%) headache 0% (placebo 3.8%) NCT02980692 · Phase 2 · registry result, not featured evidence I headache 3.8% (placebo 3.8%) aspartate aminotransferase increased 2.6% (placebo 0%) nasopharyngitis 2.6% (placebo 6.3%) NCT02980692 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
risankizumab
show 2 more results
show 6 more results
show 6 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
+ 2 further endpoints in the CSV export.
tildrakizumab
show 31 more results
show 31 more results
show 27 more results
show 3 more results
show 27 more results
show 3 more results
show 27 more results
show 3 more results
show 27 more results
show 3 more results
show 27 more results
show 3 more results
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: risankizumab's landscape · tildrakizumab's landscape